Cited by 237Heart rate and cardiovascular healthHeart Rate Variability and Autonomic ControlCardiovascular and exercise physiology

Resting Heart Rate: Risk Indicator and Emerging Risk Factor in Cardiovascular Disease

Böhm, Michael, Reil, Jan-Christian, Deedwania, Prakash, Kim, Jae B., Borer, Jeffrey S.·2015·The American Journal of Medicine

Abstract

Resting heart rate is central to cardiac output and is influenced by changes occurring in numerous diseases. It predicts longevity and cardiovascular diseases, and current evidence suggests that it is also an important marker of outcome in cardiovascular disease, including heart failure. Beta-blockers improve outcomes in heart failure; however, they have effects outside reducing heart rate. Ivabradine has demonstrated efficacy in reducing rehospitalizations and mortality in heart failure and in improving exercise tolerance and reducing angina attacks in patients with coronary artery disease, whereas selective heart rate reduction may also prove to be beneficial in therapeutic areas outside those in which ivabradine has already demonstrated clinical efficacy. This review provides an update on the associations between heart rate and cardiovascular outcomes in various conditions, the experimental effects of heart rate reduction with ivabradine, and the potential new indications in cardiovascular disease.

Integrity signals

Registry

Crossref · 10.1016/j.amjmed.2014.09.016

Cites

138 of 138 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Böhm, M., Reil, J.-C., Deedwania, P., Kim, J. B., & Borer, J. S.
Affiliations
  • Universitätsklinikum des Saarlandes (DE)
  • University of California, San Francisco (US)
  • Amgen (United States) (US)
  • Cornell University (US)
Corresponding author
Böhm, Michael
Venue
The American Journal of Medicine
Publisher
Elsevier BV
Published
2015-03
Volume
128
Issue
3
Pages
219-228
ISSN
0002-9343 (ISSN-L)
OpenAlex
W2082410000
Cited by
236
References
138
Citations by year
2026: 12 · 2025: 25 · 2024: 22 · 2023: 25 · 2022: 34 · 2021: 24 · 2020: 16 · 2019: 16 · 2018: 14 · 2017: 14 · 2016: 24 · 2015: 9 · 2014: 1
FWCI
2.55
Type
journal article
Language
en
Open access
closed
Locations
  • The American Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Amgen
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
  • Health Sciences › Medicine › Complementary and alternative medicine › Cardiovascular and exercise physiology
Keywords
resting heart rate, cardiovascular risk, heart failure, ivabradine, beta-blockers, heart rate reduction, cardiovascular outcomes, coronary artery disease, mortality, hospital readmission, angina pectoris, exercise tolerance
MeSH terms
Ivabradine, Benzazepines, Cardiovascular Agents, Cardiovascular Diseases, Heart Rate, Humans, Rest, Risk Factors, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review